• About Us
  • Copyright Policy
  • Disclaimer
  • Authors
  • Career
  • Contact Us
Assamese |   Bengali |  
Sunday, April 18, 2021
NORTHEAST NOW
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion
No Result
View All Result
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion
No Result
View All Result
NORTHEAST NOW
Assamese
Home Health

India’s first Coronavirus vaccine will be at least 60% effective: Bharat Biotech

NE NOW NEWS by NE NOW NEWS
October 23, 2020 4:27 pm
Know about the 1st Covid-19 vaccine registered in Russia
Share on FacebookShare on Twitter

India’s first Covid-19 vaccine candidate Covaxin is likely to be at least 60% effective.

The vaccine candidate, which is being developed by Bharat Biotech, received approval from the drugs controller general of India (DCGI) on Thursday to conduct a Phase 3 clinical trial to establish the efficacy of their vaccine candidate.

The interim results of the Phase 3 trial are likely to be out by April or May next year.

“The benchmark for the efficacy of our anti-Covid-19 vaccine is 60%. We will be conducting the largest Phase 3 trial for Covaxin, and the efficacy results should be available by early April-May, 2021,” HT quoted Sai Prasad, executive director, Bharat Biotech International Ltd, as saying.

Prasad is a part of the product development team in Bharat Biotech.

Prasad said the WHO, US FDA (Food and Drug Administration) and even India’s Central Drugs Standard Control Organisation (CDSCO) approve a respiratory vaccine if it achieves 50% efficacy; for Covaxin, we aim to achieve at least 60%, but it could also be more.

“Chances of the vaccine being less than 50% effective are remote, as suggested by our trial results so far, which include results from animal studies,” he added.

According to the current plan, the Phase 3 trial to determine vaccine efficacy will begin early to mid-November with 26,000 study subjects at 25 to 30 sites across 13-14 states.

For the Phase 1 trial, the company recruited 375 subjects, and in Phase 2, 400 subjects participated.

NORTHEAST NOW

Northeast Now is a multi-app based hyper-regional bilingual news portal. Led by a group of professionals, the digital news platform covers every inch of the eight states of northeast India and the five neighbouring countries. It is the first of its kind new media initiative in the northeast, and is based in Guwahati. As the political dynamics in the northeast is intricate and fluid, Northeast Now is always politically neutral.

 
Our Properties
 
  • NORTHEAST NOW ASSAMESE
  • NORTHEAST JOBS
  • NORTHEAST TENDERS
  • INNFINITY
  • About Us
  • Copyright Policy
  • Disclaimer
  • Authors
  • Career
  • Contact Us

© 2019 - Maintained by EZEN Software & Technology Pvt. Ltd

No Result
View All Result
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion

© 2019 - Maintained by EZEN Software & Technology Pvt. Ltd